🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. Placebo

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  2. Placebo

    Agios Netherlands B.V.

    Pyruvate Kinase Deficiency

    phase 3 small molecule completed

    1 trial

  3. Placebo

    Amneal Pharma Europe Ltd

    Asthma

    phase 3 small molecule active

    1 trial

  4. Placebo

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule completed

    1 trial

  5. Placebo

    Matinas BioPharma Holdings

    Severe Hypertriglyceridemia

    phase 3 small molecule terminated

    1 trial

  6. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsies, Partial

    phase 3 small molecule completed

    1 trial

  7. Placebo

    Takeda

    Short Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  8. Placebo

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials

  9. Placebo

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar Depression

    phase 3 small molecule completed

    1 trial

  10. Placebo

    Takeda

    Healthy Volunteers

    phase 3 small molecule completed

    2 trials

  11. Placebo

    Milestone Pharmaceuticals

    Atrial Fibrillation

    phase 3 small molecule active

    1 trial

  12. Placebo

    Regeneron UK Limited

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  13. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    ADHD

    phase 3 small molecule completed

    5 trials

  14. Placebo

    Ark Therapeutics

    Hyperphagia

    phase 3 small molecule on hold

    1 trial

  15. Placebo

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1 (PH1)

    phase 3 small molecule completed

    1 trial

  16. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  17. Placebo

    Sanofi Pasteur

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  18. Placebo (Lisaftoclax), Lisaftoclax, Azacitidine Seacross 25 mg/mL powder for suspension for injection

    Lacuna Pharma Pty Ltd

    Newly Diagnosed Higher Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  19. Placebo (Metoprolol succinate), Metoprololsuccinat STADA® 47,5 mg Retardtabletten, Aficamten, DOBUTAMINE , Placebo (Aficamten)

    Cytokinetics (Ireland) Limited

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  20. Placebo (Saline 0.9% (weight per volume; w/v)) for Pertuzumab, PERTUZUMAB, TRASTUZUMAB, PACLITAXEL, DS-8201a, DOCETAXEL

    AstraZeneca AB

    HER2-positive metastatic breast cancer

    phase 3 small molecule active

    1 trial

  21. Placebo (Vehicle) for investigational DFL24498, Isocyclosporin A, DEXAMETHASONE

    Dompe' Farmaceutici S.p.A.

    Atopic Keratoconjunctivitis

    phase 3 small molecule active

    1 trial

  22. Placebo (for alirocumab)

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule completed

    5 trials

  23. Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg), TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Hypertension Associated with Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

  24. Placebo (inhalation powder capsules) containing 1 of 4 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg or 640 µg ), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Hypertension Associated with Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources